| Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t (11; 14) T Jelinek, J Mihalyova, M Kascak, J Duras, T Popkova, K Benkova, ... American journal of hematology 94 (1), E35-E37, 2019 | 43 | 2019 |
| More than 2% of circulating tumor plasma cells defines plasma cell leukemia–like multiple myeloma T Jelinek, R Bezdekova, D Zihala, T Sevcikova, A Anilkumar Sithara, ... Journal of clinical oncology 41 (7), 1383-1392, 2023 | 41 | 2023 |
| Limited efficacy of daratumumab in multiple myeloma with extramedullary disease T Jelinek, T Sevcikova, D Zihala, T Popkova, V Kapustova, ... Leukemia 36 (1), 288-291, 2022 | 40 | 2022 |
| Monoclonal antibodies in the treatment of AL amyloidosis: co‐targetting the plasma cell clone and amyloid deposits T Popkova, R Hajek, T Jelinek British journal of haematology 189 (2), 228-238, 2020 | 34 | 2020 |
| The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma A Vdovin, T Jelinek, D Zihala, T Sevcikova, M Durech, H Sahinbegovic, ... Nature Communications 13 (1), 6820, 2022 | 16 | 2022 |
| Cytarabine+ G-CSF is more effective than cyclophosphamide+ G-CSF as a stem cell mobilization regimen in multiple myeloma T Jelinek, L Adamusova, T Popkova, I Tvrda, J Smejkalova, M Simicek, ... Bone Marrow Transplantation 54 (7), 1107-1114, 2019 | 16 | 2019 |
| Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors T Jelinek, D Zihala, T Sevcikova, A Anilkumar Sithara, V Kapustova, ... Leukemia, 1-11, 2024 | 12 | 2024 |
| Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t (11; 14): A real-world cohort T Jelinek, T Popkova, J Duras, J Mihalyova, M Kascak, K Benkova, ... Hematological oncology 38 (3), 412-414, 2020 | 12 | 2020 |
| Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti‐CD38 therapy O Venglar, V Kapustova, A Anilkumar Sithara, D Zihala, L Muronova, ... British Journal of Haematology 204 (4), 1439-1449, 2024 | 8 | 2024 |
| Management of Treatment-Related Infectious Complications in High-Risk Hemato-Oncological Patients via Telemedicine K Hradská, T Popková, M Skořupová, J Mihályová, T Jelínek, J Lančová, ... Cancer Management and Research, 1655-1661, 2022 | 5 | 2022 |
| Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine M Zátopková, T Ševčíková, V Fanfani, Z Chyra, L Říhová, R Bezděková, ... Blood Advances 6 (2), 368-372, 2022 | 5 | 2022 |
| Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies V Sandecka, T Popkova, M Stork, V Maisnar, J Minarik, A Jungova, ... Blood Cancer Journal 13 (1), 153, 2023 | 3 | 2023 |
| Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma M Vlachová, J Gregorová, P Vychytilová-Faltejsková, NA Gabło, L Radová, ... International Journal of Molecular Sciences 23 (23), 14765, 2022 | 3 | 2022 |
| Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets T Jelinek, D Zihala, T Sevcikova, V Kapustova, H Sahinbegovic, ... Blood 138, 2680, 2021 | 3 | 2021 |
| Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real‐world confirmation. J Radocha, T Jelinek, L Pour, I Spicka, J Minarik, T Popkova, A Jungova, ... International Journal of Laboratory Hematology 43 (5), 2021 | 2 | 2021 |
| P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS T Popková, L Pour, I Spicka, J Radocha, A Jungova, J Minarik, P Pavlíček, ... HemaSphere 7 (S3), e0151603, 2023 | 1 | 2023 |
| Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic T Popkova, L Pour, I Spicka, J Radocha, A Jungova, J Minarik, T Jelinek, ... Blood 138, 4894, 2021 | 1 | 2021 |
| Prognostic Value of PET/CT Performed Day+ 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma: Real-World Single Center Experience L Muronova, M Havel, T Popkova, H Plonkova, R Hajek, T Jelinek Blood 136, 6-7, 2020 | 1 | 2020 |
| Towards higher safety of haemato-oncological patients undergoing treatment T Popkova, K Hradska, J Mihalyova, M Skorupova, T Jelinek, J Duras, ... Blood 134, 4757, 2019 | 1 | 2019 |
| Level of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre‐Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients O Venglar, E Radova, D Zihala, I Tvrda, V Kubala, K Kutejova, ... American Journal of Hematology, 2025 | | 2025 |
